Seminars in Oncology
Volume 33, Issue 2 , Pages 210-219 , April 2006

Treatment of Relapsed Chronic Lymphocytic Leukemia: Old and New Therapies

  • John C. Byrd

      Affiliations

    • Corresponding Author InformationAddress correspondence to John C. Byrd, MD, Director of Hematologic Malignancies, Division of Hematology-Oncology, Starling Loving Hall, Room 302, The Ohio State University, Columbus, OH 43210, USA.
    • ,
  • Thomas S. Lin
    • ,
  • Michael R. Grever

References 

  1. Binet JL , Lepoprier M , Dighiero G , et al.   A clinical staging system for chronic lymphocytic leukemia (Prognostic significance) . Cancer . 1977;40:855–864
  2. Rai KR , Sawitsky A , Cronkite EP , et al.   Clinical staging of chronic lymphocytic leukemia . Blood . 1975;46:219–234
  3. Keating MJ , O’Brien S , Albitar M , et al.   Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia . J Clin Oncol . 2005;23:4079–4088
  4. Byrd JC , Rai K , Peterson BL , et al.   Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia (An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011) . Blood . 2005;105:49–53
  5. Grever MR , Bisaccia E , Scarborough DA , et al.   An investigation of 2′-deoxycoformycin in the treatment of cutaneous T-cell lymphoma . Blood . 1983;61:279–282
  6. Grever MR , Siaw MF , Jacob WF , et al.   The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy . Blood . 1981;57:406–417
  7. Grever MR , Kopecky KJ , Coltman CA , et al.   Fludarabine monophosphate (A potentially useful agent in chronic lymphocytic leukemia) . Nouv Rev Fr Hematol . 1988;30:457–459
  8. Byrd JC , Waselenko JK , Keating M , et al.   Novel therapies for chronic lymphocytic leukemia in the 21st century . Semin Oncol . 2000;27:587–597
  9. Keating MJ , Kantarjian H , O’Brien S , et al.   Fludarabine (A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia) . J Clin Oncol . 1991;9:44–49
  10. Keating MJ , Kantarjian H , Talpaz M , et al.   Fludarabine (A new agent with major activity against chronic lymphocytic leukemia) . Blood . 1989;74:19–25
  11. Cheson BD , Vena DA , Foss FM , et al.   Neurotoxicity of purine analogs (A review) . J Clin Oncol . 1994;12:2216–2228
  12. Keating MJ , Flinn I , Jain V , et al.   Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine (Results of a large international study) . Blood . 2002;99:3554–3561
  13. Rai KR , Peterson BL , Appelbaum FR , et al.   Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia . N Engl J Med . 2000;343:1750–1757
  14. Flinn IW , Neuberg D , Dewald GW , et al.   Fludarabine and cyclophosphamide produces a higher complete response rate and more durable remissions than fludarabine in patients with previously untreated CLL (Intergroup Trial E2997) . Blood . 2004;104:139a; (abstr 475)
  15. Eichhorst BF , Busch R , Hopfinger G , et al.   Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia . Blood . 2006;107:885–891
  16. Keating MJ , O’Brien S , Kantarjian H , et al.   Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent . Blood . 1993;81:2878–2884
  17. Keating MJ , O’Brien S , Kontoyiannis D , et al.   Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia . Leuk Lymphoma . 2002;43:1755–1762
  18. Keating MJ OBS , Kontoyiannis D , Plunkett W , et al.   Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia . Leuk Lymphoma . 2002;43:1755–1762
  19. Perkins JG , Flynn JM , Howard RS , et al.   Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma (Implications for clinical trials in this patient population) . Cancer . 2002;94:2033–2039
  20. Cordone I , Masi S , Mauro FR , et al.   p53 expression in B-cell chronic lymphocytic leukemia (A marker of disease progression and poor prognosis) . Blood . 1998;91:4342–4439
  21. Thornton PD , Gruszka-Westwood AM , et al.   Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia . Hematol J . 2004;5:47–54
  22. Lozanski G , Heerema NA , Flinn IW , et al.   Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions . Blood . 2004;103:3278–3281
  23. Dohner H , Fischer K , Bentz M , et al.   p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias . Blood . 1995;85:1580–1589
  24. Wattel E , Preudhomme C , Hecquet B , et al.   p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies . Blood . 1994;84:3148–3157
  25. Byrd JC , Smith L , Hackbarth ML , et al.   Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab . Cancer Res . 2003;63:36–38
  26. Byrd JC , Stilgenbauer S , Flinn IW . Chronic lymphocytic leukemia . Hematology (Am Soc Hematol Educ Program) . 2004;163–183
  27. Flynn JM , Byrd JC . Campath-1H monoclonal antibody therapy . Curr Opin Oncol . 2000;12:574–581
  28. Hale G , Bright S , Chumbley G . Removal of T cells from bone marrow for transplantation (A monoclonal antilymphocyte antibody that fixes human complement) . Blood . 1983;62:873–882
  29. Hale G , Dyer MJ , Clark MR , et al.   Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H . Lancet . 1988;2:1394–1399
  30. Treumann A , Lifely MR , Schneider P , et al.   Primary structure of CD52 . J Biol Chem . 1995;270:6088–6099
  31. Rowan W , Tite J , Topley P , et al.   Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells . Immunology . 1998;95:427–436
  32. Keating MJ , Flinn I , Jain V , et al.   Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine (Results of a large international study) . Blood . 2002;99:3554–3561
  33. Rai KR , Coutre S , Rizzieri D , et al.   Efficacy and safety of alemtuzumab (Campath-1H) in refractory B-CLL patients treated on a compassionate basis . Blood . 2001;98:365a; (abstr)
  34. Stilgenbauer SWD , Kröber A , Kienle D , et al.   Subcutaneous Campath-1H (alemtuzumab) in fludarabine-refractory CLL (Interim analysis of the CLL2h study of the German CLL Study Group (GCLLSG)) . Blood . 2004;104:143a; (abstr 478)
  35. Kennedy B , Rawstron A , Carter C , et al.   Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia . Blood . 2002;99:2245–2247
  36. Faderl S , Thomas DA , O’Brien S , et al.   Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies . Blood . 2003;101:3413–3415
  37. Stilgenbauer S , Dohner H . Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy . N Engl J Med . 2002;347:452–453
  38. Khorana A , Bunn P , McLaughlin P , et al.   A phase II multicenter study of Campath-1H antibody in previously treated patients with nonbulky non-Hodgkin’s lymphoma . Leuk Lymphoma . 2001;41:77–87
  39. Tang SC , Hewitt K , Reis MD , et al.   Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma . Leuk Lymphoma . 1996;24:93–101
  40. Yamauchi T , Nowak BJ , Keating MJ , et al.   DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine . Clin Cancer Res . 2001;7:3580–3589
  41. O’Brien SM , Kantarjian HM , Cortes J , et al.   Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia . J Clin Oncol . 2001;19:1414–1420
  42. Weiss MA , Maslak PG , Jurcic JG , et al.   Pentostatin and cyclophosphamide (An effective new regimen in previously treated patients with chronic lymphocytic leukemia) . J Clin Oncol . 2003;21:1278–1284
  43. Wierda W , O’Brien S , Wen S , et al.   Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for relapsed and refractory chronic lymphocytic leukemia . J Clin Oncol . 2005;23:4070–4078
  44. Thornton PD , Matutes E , Bosanquet AG , et al.   High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities . Ann Hematol . 2003;82:759–765
  45. Lin TS , Lucas MS , Byrd JC . Rituximab in B-cell chronic lymphocytic leukemia . Semin Oncol . 2003;30:483–492
  46. O’Brien SM , Kantarjian H , Thomas DA , et al.   Rituximab dose-escalation trial in chronic lymphocytic leukemia . J Clin Oncol . 2001;19:2165–2170
  47. Byrd JC , Murphy T , Howard RS , et al.   Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity . J Clin Oncol . 2001;19:2153–2164
  48. Juliusson G , Elmhorn-Rosenborg A , Liliemark J . Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine . N Engl J Med . 1992;327:1056–1061
  49. Delannoy A , Ferrant A , Martiat P , et al.   2-Chlorodeoxyadenosine therapy in advanced chronic lymphocytic leukaemia . Nouv Rev Fr Hematol . 1994;36:311–315
  50. O’Brien S , Kantarjian H , Estey E , et al.   Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy . N Engl J Med . 1994;330:319–322
  51. Byrd JC , Peterson B , Piro L , et al.   A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia (Results from CALGB Study 9211) . Leukemia . 2003;17:323–327
  52. Kantarjian HM , Ghandhi V , Kozuch P , et al.   Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers . J Clin Oncol . 2003;21:1167–1173
  53. Carlson BA , Dubay MM , Sausville EA , et al.   Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells . Cancer Res . 1996;56:2973–2978
  54. Kaur G , Stetler-Stevenson M , Sebers S , et al.   Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275 . J Natl Cancer Inst . 1992;84:1736–1740
  55. Sausville EA , Johnson J , Alley M , et al.   Inhibition of CDKs as a therapeutic modality . Ann NY Acad Sci . 2000;910:207–222
  56. Senderowicz AM , Sausville EA . Preclinical and clinical development of cyclin-dependent kinase modulators . J Natl Cancer Inst . 2000;92:376–387
  57. Worland PJ , Kaur G , Stetler-Stevenson M , et al.   Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells (Correlation with decreased H1 kinase activity) . Biochem Pharmacol . 1993;46:1831–1840
  58. Chao SH , Price DH . Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo . J Biol Chem . 2001;276:31793–31799
  59. Chao SH , Fujinaga K , Marion JE , et al.   Flavopiridol inhibits P-TEFb and blocks HIV-1 replication . J Biol Chem . 2000;275:28345–28348
  60. de Azevedo WF , Canduri F , da Silveira NJ . Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol . Biochem Biophys Res Commun . 2002;293:566–571
  61. Lam LT , Pickeral OK , Peng AC , et al.   Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol . Genome Biol . 2001;2: RESEARCH0041
  62. Kitada S , Zapata JM , Andreeff M , et al.   Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia . Blood . 2000;96:393–397
  63. Byrd JC , Shinn C , Waselenko JK , et al.   Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53 . Blood . 1998;92:3804–3816
  64. Konig A , Schwartz GK , Mohammad RM , et al.   The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines . Blood . 1997;90:4307–4312
  65. Parker BW , Kaur G , Nieves-Neira W , et al.   Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol . Blood . 1998;91:458–465
  66. Chen R , Kaur MJ , Gandhi V , et al.   Transcription inhibition by flavopiridol (mechanism of chronic lymphocytic leukemia cell death) . Blood . 2005;106:2513–2519
  67. Thomas JP , Tutsch KD , Cleary JF , et al.   Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol . Cancer Chemother Pharmacol . 2002;50:465–472
  68. Senderowicz AM , Headlee D , Stinson SF , et al.   Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms . J Clin Oncol . 1998;16:2986–2999
  69. Schwartz GK , O’Reilly E , Ilson D , et al.   Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors . J Clin Oncol . 2002;20:2157–2170
  70. Tan AR , Headlee D , Messmann R , et al.   Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms . J Clin Oncol . 2002;20:4074–4082
  71. Messmann RA , Ullmann CD , Lahusen T , et al.   Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6 . Clin Cancer Res . 2003;9:562–570
  72. Aklilu M , Kindler HL , Donehower RC , et al.   Phase II study of flavopiridol in patients with advanced colorectal cancer . Ann Oncol . 2003;14:1270–1273
  73. Schwartz GK , Ilson D , Saltz L , et al.   Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma . J Clin Oncol . 2001;19:1985–1992
  74. Stadler WM , Vogelzang NJ , Amato R , et al.   Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer (A University of Chicago Phase II Consortium study) . J Clin Oncol . 2000;18:371–375
  75. Shapiro GI , Supko JG , Patterson A , et al.   A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer . Clin Cancer Res . 2001;7:1590–1599
  76. Lin TS , Howard OM , et al.   Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma . Leuk Lymphoma . 2002;43:793–797
  77. Kouroukis CT , Belch A , Crump M , et al.   Flavopiridol in untreated or relapsed mantle-cell lymphoma (Results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group) . J Clin Oncol . 2003;21:1740–1745
  78. Flinn IW , Byrd JC , Bartlett N , et al.   Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity . Leuk Res . 2005;29:1253–1257
  79. Byrd JC , Peterson BL , Gabrilove J , et al.   Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol (Results from Cancer and Leukemia Group B study 19805) . Clin Cancer Res . 2005;11:4176–4181
  80. Byrd JC , Lin TS , Dalton JT , et al.   Flavopiridol administered as a pharmacologically-derived schedule demonstrates marked clinical activity in refractory, genetically high risk, chronic lymphocytic leukemia . Blood . 2004;104:476a; (abstr 341)
  81. Miller KC, Czuczmann MS, Dimiceli L, et al: Antileukemic effects of novel immunomodulatory agent lenalidomide (L) with or without rituximab (R) in patients (pts) with relapsed (rel) or refractory (ref) chronic lymphocytic leukemia (CLL). Encouraging preliminary results of an ongoing phase II clinical study. J Clin Oncol 23:5745, (abstr 6577)
  82. Johnson AJ , Eisenbeis CF , Cheney CM , et al.   Rituximab and 17-AAG synergistically induce apoptosis in B-cell chronic lymphocytic leukemia (CLL) . Blood . 2003;102:437a; (abstr)
  83. Byrd JC , Shinn C , Willis CR , et al.   UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism . Exp Hematol . 2001;29:703–708
  84. Virchis A , Ganeshaguru K , Hart S , et al.   A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C . Hematol J . 2002;3:131–136
  85. Hahntow IN , Schneller F , Oelsner M , et al.   Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells . Leukemia . 2004;18:747–755
  86. Byrd JC , Shinn C , Ravi R , et al.   Depsipeptide (FR901228) (A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells) . Blood . 1999;94:1401–1408
  87. Aron JL , Parthun MR , Marcucci G , et al.   Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase-8-mediated apoptosis and downregulation of c-FLIP protein . Blood . 2003;102:652–658
  88. Lucas DM , Davis ME , Parthun MR , et al.   The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells . Leukemia . 2004;18:1207–1214
  89. Rush LJ , Raval A , Funchain P , et al.   Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets . Cancer Res . 2004;64:2424–2433
  90. Byrd JC , Marcucci G , Parthun MR , et al.   A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia . Blood . 2005;105:959–967
  91. Pedersen IM , Kitada S , Schimmer A , et al.   The triterpenoid CDDO induces apoptosis in refractory CLL B cells . Blood . 2002;100:2965–2972
  92. Lee YK , Bone ND , Strege AK , et al.   VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG) in B cell chronic lymphocytic leukemia . Blood . 2002;104:788–794
  93. Campas C , Lopez JM , Santidrian AF , et al.   Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes . Blood . 2003;101:3674–3680
  94. Aloyz R , Grzywacz K , Xu ZY , et al.   Imatinib sensitizes CLL lymphocytes to chlorambucil . Leukemia . 2004;18:409–414
  95. Rai KR , O’Brien S , Cunningham C , et al.   Genasense (Bcl-2 antisense) monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia (Phase 1 and 2 results) . Blood . 2002;100:384a; (abstr 1490)
  96. Rai KR , Moore JO , Boyd TE , et al.   Phase 3 randomized trial of fludarabine/cyclophosphamide chemotherapy with or without oblimersen sodium (Bcl-2 antisense; Genasense; G3139) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) . Blood . 2004;104:102a; (abstr 338)
  97. Frankel AE , Fleming DR , Hall PD , et al.   A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia . Clin Cancer Res . 2003;9:3555–3561
  98. Mone AP , Lucas D , Aron JL , et al.   Hu1D10 induces parallel death and survival signals in chronic lymphocytic leukemia (CLL) cells (Justification for combination studies of Hu1D10 with PI3 kinase inhibitors) . Blood . 2002;100:386a; (abstr)
  99. Hopkins MT , Pathan N , Chu P , et al.   IDEC-152 (anti-CD23) triggers apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro . Blood . 2002;100:597a; (abstr)
  100. Byrd JC , Flinn I , O’Brien S , et al.   Interim results from a phase I study of lumiliximab (IDEC-152, anti-CD23 antibody) therapy for relapsed or refractory CLL . Blood . 2003;102:74a; (abstr)
  101. Cheson BD , Bennett JM , Grever M , et al.   National Cancer Institute–sponsored Working Group guidelines for chronic lymphocytic leukemia (Revised guidelines for diagnosis and treatment) . Blood . 1996;87:4990–4997
  102. Kitada S , Zapata JM , Andreeff M , et al.   Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia . Br J Haematol . 1999;106:995–1004
  103. Xia T , Georgios GV , Long L , et al.   In vitro activity of a novel fully human anti-CD40 antibody CHIR-12.12 in chronic lymphocytic leukemia (Blockade of CD40 activation and induction of ADCC) . Blood . 2004;104:703a; (abstr 2504)
  104. Zhao XB , Biswas S , Mone AP , et al.   Novel anti-CD37 small modular immunopharmaceutical (SMIP) induces B-cell-specific, caspase-independent apoptosis in human CLL cells . Blood . 2004;104:706a; (abstr 2515)

 Supported by the National Cancer Institute, The Leukemia and Lymphoma Society of America, and The D. Warren Brown Foundation.

PII: S0093-7754(06)00021-2

doi: 10.1053/j.seminoncol.2006.01.012

Seminars in Oncology
Volume 33, Issue 2 , Pages 210-219 , April 2006

Article Tools